# Cinemark Holdings, Inc.: financial statements, quarterly

CNK · NYSE · CIK 1385280 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cnk.md) · [Financials](/companies/cnk/financials.md) · [Filings](/companies/cnk/filings.md) · [Insiders](/companies/cnk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cnk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [942](/filings/0000950170-24-089583.md) | [875](/filings/0000950170-24-119234.md) | [639 d](/filings/0001193125-26-056015.md) | [579](/filings/0000950170-25-062253.md) | [734](/filings/0000950170-25-101099.md) | [922](/filings/0001193125-25-265664.md) | [814 d](/filings/0001193125-26-056015.md) | [541](/filings/0001193125-26-199037.md) | [941](/filings/0000950170-25-101099.md) | [858](/filings/0001193125-25-265664.md) | [776 d](/filings/0001193125-26-056015.md) | [643](/filings/0001193125-26-199037.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [37.1](/filings/0000950170-24-089583.md) | [38.1](/filings/0000950170-23-058496.md) | [(262) d](/filings/0000950170-24-016143.md) | [37.7](/filings/0000950170-24-051553.md) | [34.6](/filings/0000950170-24-089583.md) | [36.7](/filings/0001193125-25-265664.md) | [35.0 d](/filings/0001193125-26-056015.md) | [38.5](/filings/0001193125-26-199037.md) | [39.4](/filings/0000950170-25-101099.md) | [32.2](/filings/0001193125-25-265664.md) | [32.2 d](/filings/0001193125-26-056015.md) | [34.7](/filings/0001193125-26-199037.md) |
| Income tax | $m | [12.3](/filings/0000950170-23-038309.md) | [21.4](/filings/0000950170-23-058496.md) | [0.1 d](/filings/0001193125-26-056015.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [119](/filings/0000950170-24-089583.md) | [90.2](/filings/0000950170-24-119234.md) | [(18.0) d](/filings/0001193125-26-056015.md) | [24.8](/filings/0000950170-25-062253.md) | [45.8](/filings/0000950170-25-101099.md) | [188](/filings/0001193125-25-265664.md) | [51.3 d](/filings/0001193125-26-056015.md) | [(38.9)](/filings/0001193125-26-199037.md) | [93.5](/filings/0000950170-25-101099.md) | [49.5](/filings/0001193125-25-265664.md) | [34.1 d](/filings/0001193125-26-056015.md) | [(6.4)](/filings/0001193125-26-199037.md) |
| Diluted EPS | $ per share | [0.80](/filings/0000950170-24-089583.md) | [0.61](/filings/0000950170-24-119234.md) | not reported | [0.19](/filings/0000950170-25-062253.md) | [0.32](/filings/0000950170-25-101099.md) | [1.19](/filings/0001193125-25-265664.md) | not reported | [(0.32)](/filings/0001193125-26-199037.md) | [0.63](/filings/0000950170-25-101099.md) | [0.40](/filings/0001193125-25-265664.md) | not reported | [(0.06)](/filings/0001193125-26-199037.md) |
| Basic EPS | $ per share | [0.98](/filings/0000950170-24-089583.md) | [0.74](/filings/0000950170-24-119234.md) | not reported | [0.20](/filings/0000950170-25-062253.md) | [0.37](/filings/0000950170-25-101099.md) | [1.54](/filings/0001193125-25-265664.md) | not reported | [(0.32)](/filings/0001193125-26-199037.md) | [0.81](/filings/0000950170-25-101099.md) | [0.43](/filings/0001193125-25-265664.md) | not reported | [(0.06)](/filings/0001193125-26-199037.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2019 (2019-12-31) | Q1 FY2020 (2020-03-31) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | FY2020 (2020-12-31) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [488](/filings/0001564590-21-009190.md) | [479](/filings/0001564590-20-028134.md) | [572](/filings/0001564590-20-035881.md) | [826](/filings/0001564590-20-050836.md) | [655](/filings/0000950170-22-002035.md) | [513](/filings/0001564590-21-025286.md) | [596](/filings/0001564590-21-041893.md) | [543](/filings/0000950170-21-003152.md) | [707](/filings/0000950170-22-022048.md) | [569](/filings/0000950170-22-007987.md) | [695](/filings/0000950170-22-014938.md) | [632](/filings/0000950170-22-022048.md) |
| Current assets | $m | [635](/filings/0001564590-21-009190.md) | [588](/filings/0001564590-20-028134.md) | [745](/filings/0001564590-20-035881.md) | [984](/filings/0001564590-20-050836.md) | [893](/filings/0000950170-22-002035.md) | [755](/filings/0001564590-21-025286.md) | [720](/filings/0001564590-21-041893.md) | [669](/filings/0000950170-21-003152.md) | [874](/filings/0000950170-22-022048.md) | [720](/filings/0000950170-22-007987.md) | [873](/filings/0000950170-22-014938.md) | [801](/filings/0000950170-22-022048.md) |
| Total assets | $m | [5,828](/filings/0001564590-21-009190.md) | [5,633](/filings/0001564590-20-028134.md) | [5,690](/filings/0001564590-20-035881.md) | [5,803](/filings/0001564590-20-050836.md) | [5,563](/filings/0000950170-22-002035.md) | [5,297](/filings/0001564590-21-025286.md) | [5,213](/filings/0001564590-21-041893.md) | [5,079](/filings/0000950170-21-003152.md) | [5,231](/filings/0000950170-22-022048.md) | [5,024](/filings/0000950170-22-007987.md) | [5,004](/filings/0000950170-22-014938.md) | [4,851](/filings/0000950170-22-022048.md) |
| Current liabilities | $m | [709](/filings/0001564590-21-009190.md) | [600](/filings/0001564590-20-028134.md) | [596](/filings/0001564590-20-035881.md) | [624](/filings/0001564590-20-050836.md) | [606](/filings/0000950170-22-002035.md) | [595](/filings/0001564590-21-025286.md) | [652](/filings/0001564590-21-041893.md) | [643](/filings/0000950170-21-003152.md) | [769](/filings/0000950170-22-022048.md) | [646](/filings/0000950170-22-007987.md) | [726](/filings/0000950170-22-014938.md) | [628](/filings/0000950170-22-022048.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [1,771](/filings/0001564590-21-009190.md) | [1,870](/filings/0001564590-20-028134.md) | [2,117](/filings/0001564590-20-035881.md) | [2,366](/filings/0001564590-20-050836.md) | [2,377](/filings/0000950170-22-002035.md) | [2,477](/filings/0001564590-21-025286.md) | [2,479](/filings/0001564590-21-041893.md) | [2,477](/filings/0000950170-21-003152.md) | [2,476](/filings/0000950170-22-022048.md) | [2,477](/filings/0000950170-22-007987.md) | [2,475](/filings/0000950170-22-014938.md) | [2,474](/filings/0000950170-22-022048.md) |
| Current portion of debt | $m | [6.6](/filings/0001564590-21-009190.md) | [6.6](/filings/0001564590-20-028134.md) | [7.3](/filings/0001564590-20-035881.md) | [8.0](/filings/0001564590-20-050836.md) | [18.1](/filings/0000950170-22-002035.md) | [18.5](/filings/0001564590-21-025286.md) | [20.9](/filings/0001564590-21-041893.md) | [20.3](/filings/0000950170-21-003152.md) | [24.3](/filings/0000950170-22-022048.md) | [27.2](/filings/0000950170-22-007987.md) | [25.7](/filings/0000950170-22-014938.md) | [22.0](/filings/0000950170-22-022048.md) |
| Shareholders' equity | $m | [1,436](/filings/0001564590-21-009190.md) | [1,253](/filings/0001564590-20-028134.md) | [1,087](/filings/0001564590-20-035881.md) | [1,007](/filings/0001564590-20-050836.md) | [788](/filings/0000950170-22-002035.md) | [514](/filings/0001564590-21-025286.md) | [387](/filings/0001564590-21-041893.md) | [304](/filings/0000950170-21-003152.md) | [323](/filings/0000950170-22-022048.md) | [286](/filings/0000950170-22-007987.md) | [208](/filings/0000950170-22-014938.md) | [195](/filings/0000950170-22-022048.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2020 (2020-12-31) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(162) d](/filings/0000950170-22-002035.md) | [(124)](/filings/0000950170-22-007987.md) | [103 d](/filings/0000950170-22-014938.md) | [(20.8) d](/filings/0000950170-22-022048.md) | [208 d](/filings/0000950170-22-002035.md) | [(119)](/filings/0000950170-22-007987.md) | [165 d](/filings/0000950170-22-014938.md) | [(18.4) d](/filings/0000950170-22-022048.md) | not reported | not reported | not reported | not reported |
| Capital expenditure | $m | [16.3 d](/filings/0000950170-23-004235.md) | [17.7](/filings/0000950170-22-007987.md) | [15.1](/filings/0001564590-21-041893.md) | [24.4](/filings/0000950170-21-003152.md) | [38.3 d](/filings/0000950170-23-004235.md) | [18.7](/filings/0000950170-23-018072.md) | [21.9](/filings/0000950170-23-038309.md) | [24.7](/filings/0000950170-23-058496.md) | [45.4 d](/filings/0000950170-23-004235.md) | [26.3](/filings/0000950170-23-018072.md) | [28.3](/filings/0000950170-23-038309.md) | [35.1](/filings/0000950170-23-058496.md) |
| Dividends paid | $m | [0.0 d](/filings/0000950170-22-002035.md) | not reported | not reported | not reported | [0.0 d](/filings/0000950170-22-002035.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [118](/filings/0000950170-23-038309.md) | [118](/filings/0000950170-23-058496.md) | [119](/filings/0000950170-24-051553.md) | [152](/filings/0000950170-24-089583.md) | [152](/filings/0000950170-24-119234.md) | [152](/filings/0000950170-25-062253.md) | [153](/filings/0000950170-25-101099.md) | [158](/filings/0001193125-25-265664.md) | [119](/filings/0001193125-26-199037.md) | [149](/filings/0000950170-25-101099.md) | [124](/filings/0001193125-25-265664.md) | [115](/filings/0001193125-26-199037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 120,424,973 at 2022-10-28, from the cover of the [10-Q filed 2022-11-04](/filings/0000950170-22-022048.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.